OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Jussi Holmalahti is head of section (generics) at the National Agency for Medicines, PO Box 55, FIN-00301 Helsinki, Finland. Tel. +358 9 47334 239 Fax +358 9 47334 333 email@example.com
June 01, 2004
The content and quality of information supplied with drug products are among the most specifically defined areas associated with the products for sale. For patient or drug user, the information is presented in patient information leaflets (PILs) placed in the package. The readability testing of PILs is an important stage in the process of making the texts contained in the summary of product characteristics comprehensible to users, as this article discusses.